ArticleBlood advances2022

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Andrew F Berdel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.